Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Inherit Metab Dis ; 43(4): 880-890, 2020 07.
Article in English | MEDLINE | ID: mdl-32064623

ABSTRACT

Congenital disorders of glycosylation (CDGs) are clinically heterogeneous disorders defined by a decreased ability to modify biomolecules with oligosaccharides. Critical disruptions in protein recognition, interaction, binding, and anchoring lead to broad physiological effects. Patients present with endocrinopathy, immunodeficiency, hepatopathy, coagulopathy, and neurodevelopmental impairment. Patients may experience mortality/morbidity associated with shock physiology that is frequently culture negative and poorly responsive to standard care. Oedema, pleural and pericardial effusions, ascites, proteinuria, and protein-losing enteropathy are observed with an exaggerated inflammatory response. The negative serum protein steady state results from several mechanisms including reduced hepatic synthesis and secretion, increased consumption, and extravasation. Disruption of the glycocalyx, a layer of glycosylated proteins that lines the endothelium preventing thrombosis and extravasation, is a suspected cause of endothelial dysfunction in CDG patients. We performed a retrospective review of CDG patients admitted to our institution with acute illness over the past 2 years. Longitudinal clinical and laboratory data collected during the sick and well states were assessed for biomarkers of inflammation and efficacy of interventions. Six patients representing 4 CDG subtypes and 14 hospitalisations were identified. Acute D-dimer elevation, proteinuria, decreased serum total protein levels, coagulation proteins, and albumin were observed with acute illness. Infusion of fresh frozen plasma, and in some cases protein C concentrate, was associated with clinical and biomarker improvement. This was notable with intra-patient comparison of treated vs untreated courses. Use of endothelial barrier support therapy may reduce endothelial permeability by restoring both regulatory serum protein homeostasis and supporting the glycocalyx and is likely a critical component of care for this population.


Subject(s)
Congenital Disorders of Glycosylation/metabolism , Congenital Disorders of Glycosylation/therapy , Endothelial Cells/metabolism , Glycocalyx/metabolism , Thrombosis/prevention & control , Biomarkers/metabolism , Capillary Permeability/physiology , Child , Child, Preschool , Endothelium, Vascular/metabolism , Female , Fibrin Fibrinogen Degradation Products/metabolism , Humans , Infant , Male , Plasma , Retrospective Studies
2.
Nano Lett ; 16(1): 177-81, 2016 Jan 13.
Article in English | MEDLINE | ID: mdl-26654461

ABSTRACT

We report a phototriggerable formulation enabling in vivo repeated and on-demand anesthesia with minimal toxicity. Gold nanorods (GNRs) that can convert near-infrared (NIR) light into heat were attached to liposomes (Lip-GNRs), enabling light-triggered phase transition of their lipid bilayers with a consequent release of payload. Lip-GNRs containing the site 1 sodium channel blocker tetrodotoxin and the α2-adrenergic agonist dexmedetomidine (Lip-GNR-TD) were injected subcutaneously in the rat footpad. Irradiation with an 808 nm continuous wave NIR laser produced on-demand and repeated infiltration anesthesia in the rat footpad in proportion to the irradiance, with minimal toxicity. The ability to achieve on-demand and repeated local anesthesia could be very beneficial in the management of pain.


Subject(s)
Anesthesia, Local/methods , Dexmedetomidine/administration & dosage , Nanotubes/chemistry , Tetrodotoxin/administration & dosage , Animals , Dexmedetomidine/chemistry , Drug Delivery Systems , Gold/chemistry , Humans , Light , Liposomes/administration & dosage , Liposomes/chemistry , Rats , Tetrodotoxin/chemistry
3.
Pediatr Dev Pathol ; 10(6): 491-9, 2007.
Article in English | MEDLINE | ID: mdl-18001158

ABSTRACT

Kawasaki disease (KD) is a systemic vasculitis condition with a relatively unknown etiology. First described in 1967 by Tomisaku Kawasaki in Japan, KD has come to be widely diagnosed in every region of the world. The disease has a high prevalence in children ages 6 months to 5 years, particularly in those of Japanese descent. Patients often present with a high fever, rash, lymphadenopathy, and conjunctival injections, but there is no diagnostic test for KD. This paper presents data from our Kawasaki registry including 99 patients with emphasis on Kawasaki cardiopathy. Three patients died from complications of KD, and 1 patient underwent heart transplant for massive aneurysmal dilatation. The 4 explanted hearts showed a spectrum of pathological findings (acute thrombosis, vasculitis, and myocarditis), and 1 patient showed the long-term sequelae of vasculitis in the form of massive aneurysmal dilatation. Among the survivors, 30% showed aneurysmal dilatation. This paper reviews the most recent information regarding Kawasaki cardiopathy and underlying molecular mechanisms.


Subject(s)
Heart Diseases/pathology , Mucocutaneous Lymph Node Syndrome/pathology , Adult , Child , Fatal Outcome , Female , Heart Diseases/etiology , Humans , Infant , Male , Mucocutaneous Lymph Node Syndrome/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...